Neurocrine Biosciences | Des Atouts



Assets Changement Date
AbbVie USD 135.16B 8.26B 2024-12
Acadia Pharmaceuticals USD 1.13B 55.39M 2025-03
Agios Pharmaceuticals USD 1.56B 107.68M 2025-03
ALKERMES USD 2.08B 26.41M 2025-03
Alnylam Pharmaceuticals USD 4.21B 26.17M 2025-03
Amgen USD 89.37B 2.47B 2025-03
Biogen USD 28.03B 16.2M 2025-03
BioMarin Pharmaceutical USD 7.15B 158.07M 2025-03
Cytokinetics USD 1.26B 137.62M 2025-03
Dynavax Technologies USD 945.93M 40.33M 2025-03
Exelixis USD 2.84B 110.44M 2025-04
Gilead Sciences USD 56.43B 2.56B 2025-03
Halozyme Therapeutics USD 2.2B 133.06M 2025-03
Incyte USD 5.75B 305.04M 2025-03
Ionis Pharmaceuticals USD 2.81B 190.73M 2025-03
Neurocrine Biosciences USD 3.72B 183.7M 2024-12
Pfizer USD 208.03B 5.37B 2025-03
Prothena USD 547.11M 48.15M 2024-12
Regeneron Pharmaceuticals USD 37.55B 214.2M 2025-03
Repligen USD 2.85B 22.48M 2025-03
Sarepta Therapeutics USD 3.47B 497.79M 2025-03
Teva Pharmaceutical Industries USD 38.42B 911M 2025-03
Ultragenyx Pharmaceutical USD 1.31B 191.53M 2025-03
Vertex Pharmaceuticals USD 22.53B 293M 2024-12



Neurocrine Biosciences Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.